Navigation Links
InterMune Reports Third Quarter 2011 Financial Results and Business Highlights
Date:11/3/2011

d for marketing by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States.  Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.
For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to commercial launch preparations for Esbriet® (pirfenidone) in the EU, anticipated timing of commercial launches and statements regarding anticipated timing of the ASCEND trial enrollment and availability of results.  All forward-looking statements and other information included in this press release are based on information available to InterMune as of the date hereof, and InterMune assumes no obligation to update any such forward-looking statements or information.  InterMune's actual results could differ materially from those described in InterMune's forward-looking statements.  

Other factors that could cause or contribute to such differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 9, 2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the fact that physician prescriptions of Actimmune
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. InterMune Announces Pricing of Concurrent Public Offerings of 4,000,000 Shares of Common Stock and $135 Million Principal Amount of Convertible Senior Notes
2. InterMune to Release Second Quarter Financial Results on August 4
3. InterMune Initiates Phase 3 ASCEND Study of Pirfenidone in IPF
4. InterMune to Webcast 2011 Analyst Day Presentations
5. InterMune Announces Presentation of Positive Pirfenidone Data at the International Conference of the American Thoracic Society (ATS)
6. InterMune to Present at Bank of America Merrill Lynch Health Care Conference
7. InterMune Reports First Quarter 2011 Financial Results and Business Highlights
8. InterMune to Release First Quarter Financial Results on April 28
9. InterMune to Release Fourth Quarter and Full Year Financial Results on February 16
10. InterMune Announces Senior Leadership Appointments to Prepare for Launch of Esbriet™ (Pirfenidone) in Europe
11. InterMune to Release Third Quarter Financial Results on October 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... (PRWEB) May 21, 2015 Patent Offering, ... method for diagnostic or therapeutic imaging within a body ... uses an endoscope having a low cost, single-use disposable ... filing date was October 18, 2013 and the patent ... technology enables the physician to customize the lighting and ...
(Date:5/21/2015)... DUBLIN , May 20, 2015 Research ... announced the addition of the "2015 Global ... to their offering. The primary goal ... of flow cytometry instruments and reagents. Key information ... drive the selection of flow cytometers, predominantly used ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Global Survey on Flow Cytometry Adoption Trends 2015 2Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... is making,progress in the development of sustainable biofuels. The recent first crop of,genetically modified poplars of the Flemish Institute for Biotechnology (VIB),will be modified into bioethanol in a Flemish-Dutch pilot ... , ... ... ...
... He is joined by scientists scattered from Ann Arbor to Osaka on the annual Thomson Reuters list of the world,s 12 hottest researchers. , ... , ... ... ...
... ... Kimberly Thompson wins $5,000 in CUNY Nobel Science Challenge. , ... New York, NY (Vocus) March 12, 2010 -- Borough ... the economics category of the 2009 CUNY Nobel Science Challenge—as well as $5,000 as an ...
Cached Biology Technology:Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 2Bio Base Europe: Flanders and the Netherlands Cooperate on Biofuels From Genetically Modified Poplars 3Thomson Reuters Names the World's 'Hottest' Researchers 2Thomson Reuters Names the World's 'Hottest' Researchers 3Thomson Reuters Names the World's 'Hottest' Researchers 4Thomson Reuters Names the World's 'Hottest' Researchers 5BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2
(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/18/2015)... May 18, 2015 Fingerprint Cards (FPC) ... FPC1025, FPC1145, FPC1155 and FPC1035 from one if its module ... and including Q3 2015 and the sensors will be used ... order values for 2015 hereby amount to 740 MSEK to ... of 140 MSEK and a number of smaller orders not ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... German . The Deutsche Forschungsgemeinschaft (DFG, German Research ... was taken by the DFG,s Senate at its February session ... with the opportunity to address current and urgent issues in ... Like all DFG Research Units, the new facilities will take ...
... well-known limestone cave in East Timor have been discovered by a ... archaeologists and palaeontologists were working in Lene Hara Cave on the ... floor at a colleague sitting on a ledge, my head torch ... Ken Aplin said. "I shone the torch around and saw ...
... The daughters of rats who took folic acid supplements before ... twice as high as other rats, according to a new ... a faster rate, according to the study led by Dr. ... Kim stressed more research needs to be done to determine ...
Cached Biology News:DFG establishes 9 new research units 2DFG establishes 9 new research units 3DFG establishes 9 new research units 4DFG establishes 9 new research units 5DFG establishes 9 new research units 6DFG establishes 9 new research units 7Giant rats lead scientists to ancient face carvings 2Offspring of female rats given folic acid supplements develop more breast cancer 2
Mycoplasma and virus tested...
Edited by I.H. Pawlowitzki, J.H. Edwards and E.A. Thompson (1997) • This volume covers: Linkage in dominant recessive and oligogenic disease, Model free (non-parametric) methods, Tools for gene ...
...
... MS/MS analysis & ... identified across multiple samples. ... scores for increased confidence. ... accurate information from your ...
Biology Products: